Doris Hansen

May 28, 2024 | targetedonc.com | Doris Hansen

Doris Hansen, MD, assistant member, Moffitt Cancer Center department of blood and marrow transplant and cellular immunotherapy, discusses the efficacy of daratumumab (Darzalex), lenalidomide (Revlimid), and dexamethasone (DRd) compared with bortezomib (Velcade), lenalidomide, and dexamethasone (VRd) in newly diagnosed myeloma.

Apr 11, 2024 | nature.com | Aimaz Afrough |Doris Hansen |Surbhi Sidana |Lauren C. Peres |Danai Dima |Joseph McGuirk | +6 more

Idecabtagene vicleucel (ide-cel) the first FDA-approved gene therapy for relapsed refractory multiple myeloma (RRMM). However, its administration presents challenges in logistical management, selecting bridging therapy (BT), and customizing T-cell manufacturing, a complex process spanning several weeks [1]. In the KarMMa trial, BT was allowed but limited to specific prior drug classes (e.g., dexamethasone, cyclophosphamide (Cy), daratumumab, carfilzomib, bortezomib, or pomalidomide) [2].